Research programme: LFA-1 inhibitors - Actinobac Biomed

Drug Profile

Research programme: LFA-1 inhibitors - Actinobac Biomed

Alternative Names: Leukocyte function antigen-1 (LFA-1) antagonist - Actinobac Biomed; Leukothera

Latest Information Update: 03 Apr 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Medicine & Dentistry of New Jersey
  • Developer Actinobac Biomed
  • Class Biological toxins
  • Mechanism of Action Lymphocyte function-associated antigen-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Haematological malignancies; HIV infections; Psoriasis

Most Recent Events

  • 28 Mar 2013 Leukothera® is still in preclinical development for Haematological malignancies in US
  • 27 Jun 2011 Interim pharmacodynamics data from a preclinical trial in Haematological malignancies released by Actinobac
  • 16 Jun 2011 Preclinical trials in Autoimmune disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top